Shareholders that lost money on Skye Bioscience, Inc. (SKYE) Urged to Join Class Action - Contact The Gross Law Firm to Learn More

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead product candidate, nimacimab, which was claimed to be less effective than represented [1][2]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [1]. - Allegations include that the company overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares during the class period are encouraged to register for the class action by January 16, 2026, to potentially become lead plaintiffs [2]. - Registered shareholders will receive updates through a portfolio monitoring software throughout the case lifecycle [2]. Group 3: Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [3].